Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Chi-Med Loan Facility

12 Dec 2011 07:00

RNS Number : 7429T
Hutchison China Meditech Limited
12 December 2011
 



 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

  

Chi-Med Loan Facility

 

 

London: Monday, 12 December 2011: Chi-Med today announces the raising of a new three-year term loan facility as detailed below:

 

·; Chi-Med's wholly owned subsidiary, Hutchison China MediTech Finance Holdings Limited ("HCMFH") has been granted a term loan facility of up to a principal amount of HK$210 million (approximately US$27.0 million) by an independent financial institution (the "Lender") for a term of 3 years under a term loan facility agreement (the "Loan Agreement") made between HCMFH, Hutchison Whampoa Limited ("HWL"), a substantial shareholder of Chi-Med, and the Lender on 9 December 2011.

 

·; On 9 December 2011, HCMFH entered into a guarantee fee agreement (the "Guarantee Fee Agreement") with HWL, under which a guarantee fee (the "Guarantee Fee") shall be payable by HCMFH to HWL quarterly in advance in consideration of HWL guaranteeing the entire repayment obligations of HCMFH under the Loan Agreement. The Guarantee Fee is of an amount equivalent to 1.75% per annum of the amount of the facility under the Loan Agreement.

 

·; In addition to the Guarantee Fee Agreement, as a condition of HWL providing the guarantee under the Loan Agreement, Chi-Med has on 9 December 2011 issued a letter of indemnity (the "Indemnity Letter") to HWL whereby Chi-Med agrees to indemnify HWL against all or any of its damages and losses arising from the provision of the guarantee under the Loan Agreement and any breach of the Guarantee Fee Agreement by HCMFH.

 

·; The terms of the Guarantee Fee Agreement and the Indemnity Letter are considered by the directors of Chi-Med, having consulted with its nominated adviser Lazard & Co., Limited to be fair and reasonable insofar as the shareholders of Chi-Med are concerned.

 

Christian Hogg, Chi-Med CEO said: "The loan facility we have arranged represents, in our view, the most practical, cost efficient and non-dilutive financing option for Chi-Med."

 

Ends

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

Mobile: +44 (0) 7973 611 888

Mobile: +44 (0) 7967 566 919

Lazard & Co., Limited

Paul Gismondi

Nick Fowler

Telephone: +44 (0) 20 7187 2000

 

 

About Chi-Med

 

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUAAARABAUAAA
Date   Source Headline
5th Jun 20269:30 amRNSBlock Admission Application
22nd May 20267:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
21st May 202611:00 amRNS-RNMPA approval for ELUNATE with TYVYT
12th May 202612:45 pmRNSAnnouncement on Results of Annual General Meeting
30th Apr 20269:30 amRNSTotal Voting Rights
29th Apr 202611:00 amRNS-RHUTCHMED Announces NDA Acceptance in China
9th Apr 20269:30 amRNS2025 Annual Report and Notice of AGM
9th Apr 20267:00 amRNS-RData to be Presented at AACR Annual Meeting 2026
23rd Mar 20267:00 amRNS-RHUTCHMED Initiates Phase III Trial of HMPL-760
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
9th Mar 20269:30 amRNSUpdate on Licensed Oncology Product in China
6th Mar 20268:30 amRNSDirectorate change
5th Mar 20261:00 pmRNS-RPublication of Form 20-F
5th Mar 202611:00 amRNS2025 Full Year Results and Business Updates
4th Mar 20268:30 amRNS-RHUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 20268:30 amRNSHUTCHMED to Announce 2025 Final Results
14th Jan 20267:00 amRNS-RPublication of Phase III Results in The Lancet
7th Jan 20267:00 amRNS-RPositive Topline Results of Phase III Trial
5th Jan 20267:00 amRNS-RSurufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
17th Dec 20257:00 amRNS-RHUTCHMED Initiates Development of ATTC Candidate
8th Dec 20257:00 amRNSExpanded NRDL Coverage + CIDL Inclusion in China
28th Nov 20258:30 amRNSTotal Voting Rights
27th Nov 20257:00 amRNS-RHUTCHMED Highlights Data at ESMO and ASH
5th Nov 20257:00 amRNS-REnrollment Complete in SAFFRON Global Phase III
3rd Nov 20257:00 amRNS-RUpdates from R&D Event
23rd Oct 20257:00 amRNS-RHUTCHMED Presents Data at AACR NCI EORTC
21st Oct 20259:30 amRNSVesting of awards under Long Term Incentive Plan
14th Oct 20259:30 amRNSAppointment of Independent Non-executive Director
13th Oct 20257:05 amRNS-RData to be Presented at the 2025 ESMO Congress
2nd Oct 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ESMO
30th Sep 20259:30 amRNSTotal Voting Rights
12th Sep 20257:00 amRNS-RHUTCHMED to Present R&D Updates on October 31 2025
5th Sep 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at CSCO
26th Aug 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase III Trial
7th Aug 202512:00 pmRNS2025 Interim Results
3rd Jul 20259:30 amRNSHUTCHMED to Announce 2025 Half-Year Results
2nd Jul 202510:00 amRNSUpdate on Joint Corporate Brokers in London
30th Jun 20259:30 amRNSChina Approval based on Phase III SACHI Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.